🔗 Share this article

Given that the US undertakes sweeping adjustments to its immunization guidelines, an unexpected name appears somewhat surprisingly: Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by questioning COVID-19 shots during the pandemic and has concentrated on possible deaths following COVID-19 vaccination in her recent tenure at the Food and Drug Administration.

Proposed Shifts to Pediatric Immunization Schedule

Health officials planned to reveal sweeping revisions to the pediatric vaccine schedule recently, synchronizing the US with the Danish vaccine program, sources say – a substantial departure that would put the US out of step with many the global community with little proof for benefit. The announcement has been postponed until the coming year.

In place of the top vaccines chief, Dr. Høeg is set to present at the meeting. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to run the office this year.

Consolidating Power at the FDA

The acting appointment might represent a closer partnership between the drug and biologics divisions as Dr. Høeg and Prasad solidify control at the FDA – and it points to a renewed priority upon reevaluating already-approved vaccines at the FDA.

The new acting director has frequently advocated for halting certain pediatric immunization guidelines in the US so as to align more like Denmark's approach, a nation with nationalized medicine and a population approximately the size of the state of Wisconsin.

In her initial statements, she has kept her attention on vaccination policy – typically the responsibility of Dr. Prasad, head of the FDA’s CBER – instead of medication approval.

Questions Over Background

Høeg has little discernible background in pharmaceutical research, approval processes or management, which has been standard for past leaders of the CBER. She has worked at the FDA as a key advisor to the FDA chief and CBER since spring.

“She doesn’t seem to have any of the qualifications” for leading the CDER, remarked a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in managing a large organization. She lacks background in industry regulation.”

Past heads of CBER would “understand legal statutes and the underlying principles of pharmaceutical innovation”, commented Janet Woodcock. “Frankly, she lacks the sort of resume that previous people who headed CBER have had.”

This division has an vast portfolio at the FDA, the former commissioner pointed out.

“The public just zeroes in on the novel medication approvals, but the generic program approves numerous off-brand pharmaceuticals. There is also a biosimilars division, over-the-counter program and other areas, and all of those must be managed,” Dr. Woodcock noted. “The area you neglect, that is the part that I always told people is going to cause problems.”

Additionally, a substantial leadership aspect to the job, which manages in excess of 5,000 staff members. “It is a enormous leadership role, if you do it right,” she added.

Agency Reaction and Contentious Programs

In response to concerns about Høeg’s fitness for the role and whether this appointment indicates increased cooperation among FDA leaders on immunizations, a spokesperson said that the “questions rely on inaccurate presumptions”.

“Her experience is consistent with the responsibilities of her job,” the spokesperson explained, noting the period Dr. Høeg spent advising the agency head on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg inherits the agency head's recently launched expedited review system, a disputed one-day drug-approval program that apparently concerned her predecessors. “By what process are these medications being picked for this expedited pathway? Who is making the choices?” Howard said. “There is a lot of confidentiality going on at the regulatory body right now.”

In general, he remarked, “the Food and Drug Administration appears to be shifting towards laxer rules of pharmaceuticals, aside from vaccines.”

Established History on Vaccines

Regarding vaccines, Høeg has a clearer, if problematic, past, Howard said. She released a study using unverified volunteer-provided data to estimate the rate of myocarditis after Covid immunization. She consulted for the Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccinations are pose a greater threat than they are.

Among her “policy goals” for the incoming federal leadership included altering rules for new vaccines and discontinuing “unnecessary” immunizations, she stated post-election on a podcast. At the agency, Dr. Høeg has allegedly suggested barring adolescent males from getting COVID-19 vaccinations.

“She’s an complete true believer who starts off with her conclusions and tailors the evidence to retrofit the science in a very deceptive, untruthful fashion,” Dr. Howard said.

Gaining Influence and a “Push for Payback”

Høeg aligned with fellow contrarians, {like|